https://www.prnewswire.com/news-releases/bioheng-biotech-announces-publication-of-impressive-results-with-cd7-targeted-allogeneic-car-t-cell-therapy-for-relapsed-or-refractory-t-cell-malignancies-301633035.html
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell...
/PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced...